Reviewing MediWound Ltd. (MDWD)’s and TRACON Pharmaceuticals Inc. (NASDAQ:TCON)’s results

Both MediWound Ltd. (NASDAQ:MDWD) and TRACON Pharmaceuticals Inc. (NASDAQ:TCON) are Biotechnology companies, competing one another. We will contrast their profitability, analyst recommendations, risk, institutional ownership, dividends, earnings and valuation.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
MediWound Ltd. 4 3.82 N/A -0.20 0.00
TRACON Pharmaceuticals Inc. 1 0.00 N/A -1.13 0.00

We can see in table 1 the earnings per share (EPS), gross revenue and valuation of MediWound Ltd. and TRACON Pharmaceuticals Inc.


Table 2 represents MediWound Ltd. (NASDAQ:MDWD) and TRACON Pharmaceuticals Inc. (NASDAQ:TCON)’s return on equity, net margins and return on assets.

Net Margins Return on Equity Return on Assets
MediWound Ltd. 0.00% -18.4% -1.7%
TRACON Pharmaceuticals Inc. 0.00% -132.9% -75.9%

Volatility and Risk

MediWound Ltd. has a 0.5 beta, while its volatility is 50.00%, thus making it less volatile than S&P 500. TRACON Pharmaceuticals Inc. on the other hand, has 2.39 beta which makes it 139.00% more volatile compared to S&P 500.


The current Quick Ratio of MediWound Ltd. is 3.8 while its Current Ratio is 4. Meanwhile, TRACON Pharmaceuticals Inc. has a Current Ratio of 2.4 while its Quick Ratio is 2.4. MediWound Ltd. is better positioned to pay off its short-term and long-term debts than TRACON Pharmaceuticals Inc.

Analyst Recommendations

The Recommendations and Ratings for MediWound Ltd. and TRACON Pharmaceuticals Inc. are featured in the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
MediWound Ltd. 0 0 2 3.00
TRACON Pharmaceuticals Inc. 0 0 1 3.00

MediWound Ltd. has an average price target of $10.25, and a 219.31% upside potential. Competitively the average price target of TRACON Pharmaceuticals Inc. is $2, which is potential 311.95% upside. The information presented earlier suggests that TRACON Pharmaceuticals Inc. looks more robust than MediWound Ltd. as far as analyst opinion.

Insider & Institutional Ownership

Roughly 37.1% of MediWound Ltd. shares are owned by institutional investors while 65.7% of TRACON Pharmaceuticals Inc. are owned by institutional investors. Insiders owned roughly 41.5% of MediWound Ltd.’s shares. Competitively, 8.89% are TRACON Pharmaceuticals Inc.’s share owned by insiders.


In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
MediWound Ltd. -28.97% -17.78% -47.87% -41.49% -53.77% -30.54%
TRACON Pharmaceuticals Inc. -16.98% -34.33% -30.49% -45.67% -82.4% -30.16%

For the past year TRACON Pharmaceuticals Inc. has weaker performance than MediWound Ltd.


On 6 of the 8 factors MediWound Ltd. beats TRACON Pharmaceuticals Inc.

MediWound Ltd., an integrated biopharmaceutical company, focuses on developing, manufacturing, and commercializing novel therapeutics products in Israel. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns. The company also develops EscharEx, which is in Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds. MediWound Ltd. was founded in 2000 and is headquartered in Yavne, Israel.

TRACON Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer, wet age-related macular degeneration (AMD), and fibrotic diseases. Its lead product candidate is TRC105, an endoglin antibody, which is in Phase III clinical trials for angiosarcoma; randomized Phase II clinical trials for renal cell carcinoma; Phase II clinical trials for soft tissue sarcoma; Phase II clinical trials for gestational trophoblastic neoplasia; Phase I/II clinical trials for hepatocellular carcinoma; Phase I clinical trial for lung cancer; Phase I/II clinical trials for breast cancer; and Phase I/II clinical trials for wet AMD. The companyÂ’s other product candidates comprise TRC102, a small molecule that is in Phase II clinical trials for mesothelioma, Phase II clinical trials for glioblastoma, Phase I clinical trial for solid tumors and lymphomas, as well as Phase I clinical trial for lung cancer; and TRC253, a small molecule high affinity competitive inhibitor of wild type androgen receptor (AR) and multiple AR mutant receptors that is in Phase I/II clinical trials for the treatment prostate cancer. Its preclinical development products include TRC205, an endoglin antibody for the treatment of fibrotic diseases; and TRC694, an orally bioavailable inhibitor of NF-kB inducing kinase for the treatment of patients with hematologic malignancies, including myeloma. The company has a strategic licensing collaboration with Janssen Pharmaceutica N.V. to develop TRC253 and TRC694; and a license agreement with Santen Pharmaceutical Co., Ltd to develop, manufacture, and commercialize DE-122, the ophthalmic formulation of TRC105, for ophthalmology indications. The company was formerly known as Lexington Pharmaceuticals, Inc. and changed its name to TRACON Pharmaceuticals, Inc. in March 2005. TRACON Pharmaceuticals, Inc. was founded in 2004 and is headquartered in San Diego, California.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.